T e past few decades have seen a greater understanding of the molecular and genetic underpinnings of tumor etiology. However, questions regarding indolent disease, metastatic colonization, dormancy, relapse, and the rapid evolution of drug resistance are inadequately addressed by the use of standard molecular and genetic characterization and standard monolayer cell culture models (1) . T e incidence of detected preinvasive neoplastic lesions-particularly for breast and prostate cancers-has increased because of improved diagnosis and access to routine screening (2) . Clinicians of en err on the side of caution and choose to aggressively treat these patients because it is dif cult to predict which patients will progress to full-blown malignancy and which will continue to have stable disease. Regrettably, therapeutic intervention in itself may induce an emergent aggressive malignant state (3) . A r e s p e c i f c phenotypic, genotypic, and cytogenetic signatures observed in patients with nonprogressive disease? Do they display distinctive morphogenetic programs that can be used in prospective studies for up-front identif cation at the time of presentation?
Another confounding fact is that patients rapidly acquire resistance to cancer therapeutics such as those that target DNA repair machinery, microtubules, and kinase signaling cascades (4) , and this compromises the duration and quality of life. T e mechanisms that drive these resistant phenotypes are poorly understood. Is this emergent state caused by the induction of resistance af er drug treatment, development of de novo resistance mechanisms, selection for preexisting resistant subpopulations, or a combination of these? T e interplay between intrinsic resistance mechanisms and physicochemical interactions of the tumor microenvironment contributes additional complexity to the determinants of contextual drug ef cacy (5).
TAKING IT TO THREE DIMENSIONS
Recently, in ef orts to "heal" the tissue, researchers have developed therapeutics that target the microenvironment, such as immune cell activation in melanoma or tumor vasculature in the breast (6) . Because tumors are largely heterogeneous and aptly described as abnormal organs, understanding their individual components may be insuf cient to predict the behavior of the whole (5). In the face of such complexity, integration of these concepts may seem daunting. In the f eld of condensed-matter physics, a paradigm shif occurred when simply knowing the laws and models for individual system components did not predict phenomena such as those observed in superconductivity, Bose-Einstein condensation, and superf uidity (7) . Instead, new theoretical and computational models were developed to address the patterns and aggregate behavior that arose from complex interactions between large numbers of diverse particles. Cancer biologists are wrestling with comparable complexities. New tools combined with reductionist approaches are under way to successfully tackle the disease in all its complexity. One such tool uses three-dimensional (3D) culture models to reconstitute features of organs that enable in vitro recapitulation of in vivo function, including spatiotemporal gradients of chemicals and oxygen tension, mechanical cues, and heterotypic crosstalk (such as between the epithelium and the stroma). Drawing on techniques from f elds such as regenerative medicine, these 3D biomimetic platforms spatially def ne multicellular assembly in an ef ort to study treatment-induced tissue responses. T ese models reconstitute some physiological complexities but allow for the dissection of problems into discrete units.
Although 2D growth on tissue culture plastic remains the de facto platform used for pharmaceutical studies, the cells grown in that setting of en adopt physiologically irrelevant morphology and signaling patterns because they do not receive the external cues that allow them to "remember" and recapitulate their in vivo functions. In their place, 3D culture models are gaining traction in the f eld of drug discovery and development. In this Perspective, we focus on two critical gaps that are thought to be translational priorities for intervention (8) : (i) preinvasive neoplasia and (ii) advanced metastatic disease.
DCIS IN A DISH
A growing number of patients are diagnosed with an intermediate state of malignancy, ductal carcinoma in situ (DCIS), or more generally, carcinoma in situ (CIS) (2) . In the breast, loss of tissue architecture concomitant with a reactive stroma indicates that normal tissue homeostasis has been compromised but that these alterations are still restricted to the site of injury (2) . T ese preinvasive lesions may remain quiescent for several decades and in some cases never progress to an invasive phenotype. Physicians are then faced with a dilemma: either recommend aggressive treatment or simply monitor the patient. Interrogation of 3D contextual models recapitulating these intermediate states may be able to explain the temporal regulation of the malignant transition and help inform clinical decisions. T us, the f rst requirement is to create 3D models that recapitulate earlystage carcinogenesis.
At the single-cell level, alterations in intracellular processes such as signal transduction, cell-cycle regulation, transcription, protein synthesis, and cell-extracellular matrix (ECM) crosstalk occur on the time scale of milliseconds to minutes and on length scales of nanometers, representative of individual enzymes, to micrometers, in measuring the diameter of a single cell (9) . T ese processes work in concert to disrupt tissue architecture and alter local ECM boundaries spanning hundreds of micrometers (10) . Newly formed aberrant organs generate new vasculature and evade immune surveillance by recruiting stromal cells to act as accomplices and to facilitate full-blown malignancy and invasion (9) .
Human breast progression series of cell lines allow in vitro examination of the transition from normal to malignant phenotypes. When these are cultured as single cells in 3D biomimetic laminin-rich ECM, they 
PERSPECTIVE
The mechanisms underlying the spatiotemporal evolution of tumor ecosystems present a challenge in evaluating drug ef cacy. In this Perspective, we address the use of three-dimensional in vitro culture models to delineate the dynamic interplay between the tumor and the host microenvironment in an ef ort to attain realistic platforms for assessing pharmaceutical ef cacy in patients.
form multicellular structures, recapitulating the progressive loss of tissue architecture and aberrant signaling associated with the transition from nonmalignant carcinoma in situ to full malignancy (11) . T e m a l i g n a n t transformation can be achieved by exogenous oncogenetic manipulation (MCF10a) or spontaneous evolution because of culture conditions (HMT3522). A similar architectural transformation has been observed by adjusting the mechanical forces of the microenvironment in 3D cell culture of nonmalignant breast epithelial cells (5, 12) . It was found that cells form normal breast acini units when cultured in the ECM, mimicking the physiological stif ness of the in vivo mammary gland, but the same cells undergo progressive loss of architecture concomitant with aberrant signaling when the stif ness of their microenvironment approaches that of the stroma surrounding a malignant tumor in vivo (12) . Introduction of transformed stromal cells such as cancer-associated fbroblasts and macrophages in heterotypic cultures also facilitates neoplastic transformation of the epithelia (5). More recently, researchers used a microf uidics device that allowed the recreation of physiologically relevant DCIS architectures and incorporation of stromal constituents (13) , thus providing an in vitro platform with which to probe possible mechanisms facilitating the transformation to an invasive phenotype (13) . T e s e results underlie the complexity of the determinants of contextual drug ef cacy, in which both the physical and biochemical properties of the microenvironment must be considered. Nevertheless, these 3D surrogate organotypic culture models provide a tractable platform in which tissue architecture can be assessed for screening existing therapies as well as those in the preclinical pipeline. A future strategy may combine tissue biopsies with phenotype-driven drug testing of 3D culture of patient-derived tissue. Emergence of progressive loss or stable architecture af er treatment may delineate those who will benef t from early intervention from those for whom treatment would be detrimental.
FORCING THE RESISTANCE
Unfortunately, by the time that many patients are diagnosed, disseminated tumor cells (DTCs) have already successfully evaded the constraints of the tissue adjacent to the primary tumor and entered into the lymphatic or vascular systems to initiate the metastatic cascade (14) . In particular, patients diagnosed with cutaneous melanoma rapidly progress to full malignancy, ultimately succumbing if not diagnosed at very early stages of the disease (15) . Metastatic disease also indicates that tumors are likely to be intrinsically resistant to treatment (16) . DTCs en route to successful metastasis encounter distinct microenvironments conveying dif erential mechanical cues, and this exposure may induce epigenetic changes and enable de novo resistance. For example, exposure to shear forces induces cytoskeletal reorganization and cell adhesion, enabling the shape changes needed for ef cient attachment to the vascular bed and organ inf ltration (17) . In vitro studies have shown that adhesion to specif c substrata renders tumor cells more treatment-resistant. Furthermore, physicochemical properties such as the bulk stif ness, oxygen tension, and ECM composition of the local microenvironment of the inf ltrated organ, along with tumor-directed tissue remodeling, might confer protection against therapeutic interventions ( Fig. 1)  (17) . Consequently, drug treatment ef ective at the primary site may be rendered impotent for metastatic tumors (Fig. 1) . Understanding Tumor cells may adopt diff erent morphologies, patterns of ECM secretion, and modes of migration to successfully colonize distal organs. Clinically, cutaneous melanoma shows a broad tissue tropism and ability to metastasize to many organs. This illustration shows the architectural complexity at each of the diverse microenvironments in which both cell type and ECM composition might aff ect treatment effi cacy. CAF, cancer-associated fi broblast.
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Bone metastasis (19) . T e incorporation of microf uidics networks to transport soluble factors such as nutrients, hormones, growth factors, and oxygen would additionally facilitate tissue homeostasis via autocrine and paracrine signaling and recreate physiologically relevant mechanical cues that are absent from traditional cell culture (20) . Recently, researchers achieved long-term dif erentiation of hepatocytes and osteoblasts, as evidenced by the f nding that these cells exhibited normal physiological properties when cultured in bioreactors for up to 3 weeks (18) . T e s e bioreactors used complex microf uidic devices to both def ne and control the microenvironments by varying oxygen tension and f uid dynamics. Combining microf uidics and 3D microfabrication of ECM scaf olds makes possible the self-assembly of organotypic structures on experimental platforms, or "organs on a chip" (18) . Complex organs such as the brain, liver, and gut have now been reconstructed by using in vitro systems (21) (22) (23) . Of all human organs, tissue engineering of human skin has proven to be one of the most successful surrogates for modeling cancer growth (24) . Commercially available cultured skin tissue can be tailored to incorporate human melanoma cell lines with characteristics of premetastatic stages: vertical growth phase (VGP) and radial growth phase (RGP) (25, 26) . T us, a future application of this technology may facilitate addressing organ-specif c metastasis by incorporating tumor cells in these organotypic models. An immediate application currently under way, however, is the addressing of drug toxicity ef ects. T e metabolic activity of the liver and the gut largely dictates the toxic ef ects of many drugs. Pharmacokinetic studies are traditionally performed in rodents or in 2D polarized intestinal cells, but several compounds have still proven toxic to humans af er such testing (21) . Toxicology screening was recently performed in a system comprising interconnected channels and chambers representative of distinct tissue types (27) . Liver, lung, and fat cells were cultured in interconnected compartments, allowing interrogation of physiologically relevant features, such as the timing of circulation and interchange of metabolites (27) . T ese units can be adapted for highthroughput technologies, in which rapid screens of patient samples can be performed to identify suitable drug targets, and emergence of resistant phenotypes may help to determine what treatment should be administered. A more extensive review on this topic has been published previously (28) . Earlier work showed the ability of tumor cells to exhibit distinct modes of motility, switching between "mesenchymal" and "amoeboid" migration to enable single-cell dissemination in three dimensions (29, 30) . T ese motilities have been conf rmed as strategies used by tumor cells in vivo by using intravital imaging in mouse studies (31, 32) . However, the coupling of 3D organotypic models with the appropriate imaging modalities to dissect the morphodynamics of these multicellular structures has been less explored. Direct visualization of noncancerous epithelial tissue undergoing acinar and branching morphogenesis revealed geometrically specif c motilities that facilitate the establishment of multicellular architecture (29, (33) (34) (35) . Using these in vitro platforms and genetic manipulation (largely informed by patient data), a resulting phenotype can be assessed for normal or tumorigenic architecture. For example, induction of extracellular signal-regulated kinase (ERK) in 3D culture of normal human mammary epithelial cells caused the cells to become randomly motile within the acini, mimicking preinvasive breast neoplastic lesions (36) . Similarly, collective invasion-a common strategy for carcinoma dissemination-was shown to be specif c to tumor cells with genotypes similar to basal epithelial cells in 3D organotypic breast cancer studies and in mice (37) .
LET'S TAKE A LOOK
T ese data suggest that a distinct type of cell motility occurs in preinvasive stages of epithelial tumor growth and hint at an underlying morphogenetic program that facilitates full-blown malignancy. Using intravital imaging af er therapy-induced cell death revealed that distinct components of the microenvironment regulated drug eff cacy. Specif cally, increased vascular leakage increased drug ef cacy, whereas the treatment-induced recruitment of immune cells regulated the durability of treatment responses (32) . Additionally, many metastatic lesions and treatment-resistant tumors are associated with overabundance of ECM proteins (10) . T e ECM proteins may act as a physical barrier against drug transport and as signaling cues to induce resistance in cancer cells. T e establishment of this protective cocoon of ECM and its relation to cell motility are currently underexplored. Further studies may yet uncover the motility determinants of colonization and organ specif city in tumor establishment and metastasis.
REALITY CHECK
T e merging of tissue engineering and cancer biology will allow for robust interrogation of contextual drug ef cacy; however, the ultimate goal remains informed patient care. Additionally, it is dif cult to reconcile the time scale of days to weeks for a typical assay with the dynamics of clinical cancers that take many years to grow. A few points must be considered in order to ensure that these technologies will generate meaningful data. Namely, all ECMs are not created equal. Natural systems such as collagen extracts and laminin-rich gels such as Matrigel (BD Biosciences, San Jose, CA) are conveniently available but vary from lot to lot in consistency of protein concentration, gel stif ness, and concentrations of growth factors, which must be monitored. Synthetic materials incorporating def ned cell ligands and proteolytic enzymes are attractive alternatives, but fabrication of these materials requires specif c expertise and larger expense. Furthermore, cell lines that may be easy to manipulate and thus commonly used may no longer show physiological relevance to patient samples (1) . Last, cells are not static but actively remodel their local environment, changing the gradients of metabolites and mechanical forces, thus disrupting the "predef ned" environment. We may have to sacrif ce a priori understanding of cellular mechanisms and focus on phenotypic outcomes at the tissue level of organization as we get closer to deciphering the laws of cancer.
